newcastl
diseas
viru
ndv
avian
viru
evalu
develop
vector
human
vaccin
emerg
pathogen
previou
studi
ndvvector
vaccin
mous
model
suggest
potenc
deliveri
inject
intranas
rout
compar
efficaci
variou
rout
deliveri
ndvvector
vaccin
nonhuman
primat
model
deliveri
ndv
vector
vaccin
combin
intranasalintratrach
rout
elicit
protect
immun
respons
deliveri
subcutan
rout
intranas
rout
alon
elicit
limit
protect
immun
respons
suggest
necess
vaccin
deliveri
lower
respiratori
tract
furthermor
direct
comparison
vaccin
base
ndv
mesogen
strain
ndvbc
similarli
design
ndv
vector
base
modifi
lentogen
strain
carri
polybas
f
cleavag
site
ndvvf
suggest
two
ndv
strain
similar
immunogen
equal
protect
continu
outbreak
emerg
viral
pathogen
highli
pathogen
avian
influenza
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
ebola
viru
other
demonstr
need
effect
vaccin
system
rapidli
adapt
novel
pathogen
vector
vaccin
one
feasibl
approach
achiev
protect
infect
pathogen
review
use
human
virus
vaccin
vector
may
serious
hamper
preexist
immun
virus
develop
vaccin
base
antigenicallydistinct
nonhuman
virus
vesicular
stomat
viru
newcastl
diseas
viru
ndv
may
repres
viabl
altern
ndv
avian
pathogen
member
avulaviru
genu
subfamili
paramyxovirina
famili
paramyxovirida
ndv
isol
divid
three
group
base
degre
virul
bird
lentogen
strain
caus
mild
nonappar
infect
larg
limit
respiratori
alimentari
tract
includ
strain
present
use
live
vaccin
chicken
ii
mesogen
stain
caus
system
infect
intermedi
sever
also
sometim
use
vaccin
poultri
iii
velogen
strain
caus
system
infect
high
mortal
rate
major
determin
ndv
virul
bird
cleavag
site
f
protein
velogen
mesogen
strain
f
cleavag
site
polybas
cleavag
mediat
ubiquit
intracellular
proteas
furin
lentogen
strain
cleavag
site
contain
fewer
basic
amino
acid
cleavag
depend
secretori
trypsinlik
proteas
present
lumin
fluid
respiratori
alimentari
tract
replac
f
cleavag
site
lentogen
strain
polybas
site
mesogen
strain
result
viru
whose
virul
intermedi
parent
lentogen
strain
mesogen
strain
cleavag
site
deriv
recent
year
other
develop
vaccin
construct
potenti
human
use
base
lentogen
mesogen
ndv
strain
well
lentogen
strain
modifi
contain
polybas
cleavag
site
mice
intraven
iv
intraperiton
ip
intranas
immun
construct
result
protect
immun
respons
howev
mice
phylogenet
anatom
distinct
human
unknown
whether
result
obtain
mice
extrapol
potenti
human
use
particular
safeti
efficaci
live
ndvvector
vaccin
depend
well
avian
viru
replic
heterolog
host
unclear
level
permiss
rodent
would
compar
primat
addit
studi
nonhuman
primat
model
relev
potenti
human
use
show
administ
combin
intratrach
rout
ndv
highli
attenu
welltoler
immunogen
protect
review
present
studi
use
nonhuman
primat
model
compar
variou
rout
immun
ndvvector
vaccin
addit
compar
immunogen
protect
efficaci
ndvvector
vaccin
base
mesogen
strain
viru
base
modifi
lentogen
strain
carri
polybas
f
cleavag
site
order
choos
vector
repres
best
balanc
immunogen
versu
veterinari
safeti
ndv
construct
base
mesogen
beaudett
c
strain
ndvbc
viru
call
ndvvf
version
lentogen
strain
la
sota
modifi
bear
polybas
f
cleavag
site
ndvbc
intermedi
virul
ndvbc
ndvla
sota
previous
modifi
ndvbc
express
hemagglutininneuraminidas
hn
protein
human
parainfluenza
viru
type
creat
ndvbc
hn
previous
modifi
ndvbc
ndvvf
express
spike
glycoprotein
sarscov
creat
ndvvf
ndvbc
respect
briefli
open
read
frame
encod
hn
protein
access
number
sarscov
protein
access
number
amplifi
pcr
insert
pm
junction
ndvbc
ndvvf
genom
express
separ
mrna
ndv
recombin
recov
amplifi
embryon
chicken
egg
titer
construct
determin
plaqu
titrat
monolay
chicken
fibroblast
cell
plate
adult
african
green
monkey
agm
cercopithecu
aethiop
confirm
seroneg
ndv
hemagglutin
inhibit
hai
assay
use
turkey
guinea
pig
erythrocyt
use
two
studi
immun
perform
previous
describ
first
studi
fig
agm
immun
ndvbchn
combin
rout
subcutan
sc
rout
dose
pfu
per
site
day
anim
receiv
second
dose
rout
either
construct
parent
ndvbc
lack
insert
neg
control
addit
group
immun
day
ndvbc
empti
vector
administ
sc
dose
pfu
per
site
result
total
experiment
group
one
control
group
see
fig
contain
anim
serum
sampl
collect
day
assess
vectorand
insertspecif
immun
respons
second
studi
fig
tabl
agm
immun
combin
rout
day
pfu
per
site
ndvbc
empti
vector
anim
ndvbc
anim
ndvvf
anim
pfu
ndvbc
rout
anim
vaccin
viru
shed
determin
tracheal
lavag
tl
sampl
taken
day
first
dose
previous
describ
assess
serum
mucos
antibodi
respons
serum
nasopharyng
wash
nw
tl
sampl
collect
day
previous
describ
assess
protect
efficaci
vaccin
anim
studi
two
challeng
day
combin
rout
tissuecultureinfectiousdoseunit
tcid
sarscov
per
site
previous
describ
nw
tl
sampl
collect
day
postchalleng
measur
challeng
sarscov
shed
two
day
postchalleng
anim
sacrif
triplic
cm
sampl
taken
seven
region
lung
left
hilar
region
left
upper
lower
lobe
right
hilar
region
right
upper
middl
lower
lobe
one
sampl
tissu
fix
neutral
buffer
formalin
immunohistochem
ihc
histopatholog
analysi
remain
two
sampl
organ
homogen
medium
invitrogen
carlsbad
ca
usa
achiev
final
concentr
wv
sarscov
titer
supernat
determin
titrat
describ
primat
experi
perform
bioqual
inc
rockvil
md
usa
site
approv
associ
assess
accredit
laboratori
care
intern
protocol
approv
anim
care
use
committe
niaid
ndv
titer
determin
plaqu
titrat
monolay
cell
infect
monolay
cover
methylcellulos
overlay
incub
four
day
stain
crystal
violet
solut
titer
determin
plaqu
titrat
monolay
rhesu
monkey
kidney
cell
infect
monolay
cover
methylcellulos
overlay
incub
day
thereaft
monolay
fix
plaqu
immunostain
rabbit
antiserum
rais
purifi
virion
goat
antirabbit
secondari
antibodi
conjug
horseradish
peroxidas
kpl
gaithersburg
md
plaqu
visual
use
peroxidas
substrat
kpl
inc
gaithersburg
md
usa
count
sarscov
titer
tcid
per
ml
determin
limit
dilut
monolay
vero
cell
examin
visibl
cytopatholog
day
postinfect
endpoint
calcul
method
reed
muench
studi
assess
plaqu
size
ndvbc
variou
temperatur
ndv
inocula
serial
dilut
medium
use
infect
replic
plate
cell
h
well
receiv
overlay
medium
contain
methylcellulos
plate
incub
four
day
cell
day
cell
indic
temperatur
cell
monolay
stain
crystal
violet
plaqu
count
cell
monolay
fix
plaqu
immunostain
use
chicken
antindv
primari
antibodi
charl
river
lab
wilmington
usa
rabbit
antichicken
horseradish
peroxidas
conjug
secondari
antibodi
jackson
immunoresearch
laboratori
inc
west
grove
pa
usa
plaqu
visual
use
peroxidas
substrat
kpl
inc
gaithersburg
md
usa
count
evalu
plaqu
size
cell
monolay
infect
cover
medium
contain
methylcellulos
incub
day
plaqu
stain
plaqu
diamet
pixel
calcul
analysi
digit
imag
use
adob
photoshop
extend
adob
san
jose
ca
usa
assess
growth
kinet
virus
triplic
monolay
cell
plate
infect
multipl
infect
per
cell
moi
pfu
analysi
singl
step
growth
moi
pfu
analysi
multistep
growth
h
incub
indic
temperatur
well
wash
time
growth
medium
overlaid
ml
per
well
growth
medium
time
point
medium
remov
well
replac
fresh
medium
viru
titer
time
point
determin
plaqu
titrat
describ
analyz
antigen
express
follow
infect
cell
monolay
infect
moi
pfu
ndvbc
ndvbc
monolay
lyse
variou
time
point
addit
nupag
ld
sampl
buffer
invitrogen
contain
directli
cell
lysat
denatur
min
separ
sdspage
use
nupag
novex
bi
tri
gel
invitrogen
gel
analyz
western
blot
use
polyvinyliden
fluorid
membran
invitrogen
either
chicken
polyclon
antibodi
direct
ndv
charl
river
laboratori
intern
inc
germantown
md
usa
rabbit
polyclon
antibodi
abcam
cambridg
usa
ndvspecif
serum
antibodi
titer
determin
hai
assay
use
turkey
guinea
pig
erythrocyt
respect
previous
describ
antibodi
specif
sarscov
protein
detect
either
iga
igg
isotypespecif
elisa
previous
describ
prior
elisa
nw
tl
sampl
concentr
final
volum
ml
use
vivaspin
molecular
weight
cutoff
column
sartoriu
corp
edgewood
ny
usa
account
differ
sampl
collect
process
nw
tl
iga
titer
normal
total
iga
content
sampl
previous
describ
also
perform
sarscov
neutral
assay
serum
sampl
previous
describ
experi
involv
infecti
sarscov
done
biosafeti
level
condit
fix
tissu
sampl
embed
paraffin
section
use
hematoxylin
eosin
stain
immunostain
sarscov
antigen
ihc
analysi
tissu
section
first
treat
food
steamer
diva
solut
biocar
concord
ca
usa
retriev
antigen
sarscov
antigen
visual
immunostain
mous
monoclon
antibodi
sarscov
nucleoprotein
n
abcam
cambridg
usa
dilut
follow
treatment
section
dako
envis
mous
polym
link
dako
carpinteria
ca
usa
diaminobenzidin
chromogen
first
compar
ndv
vaccin
immunogen
administ
either
combin
init
rout
sc
rout
agm
four
anim
per
group
inocul
one
two
dose
day
apart
ndvbc
vector
express
hn
protein
ndvbc
hn
either
combin
init
rout
sc
rout
fig
addit
group
anim
receiv
empti
ndvbc
vector
combin
init
sc
rout
serum
sampl
collect
day
day
first
dose
day
second
dose
analyz
hai
presenc
antibodi
specif
ndv
vector
hn
insert
anim
receiv
ndv
construct
combin
init
rout
detect
ndvspecif
antibodi
fig
neither
one
two
dose
ndvbchn
administ
sc
rout
result
detect
ndv
hai
respons
similar
result
obtain
respons
either
one
two
dose
ndvbchn
administ
combin
init
rout
induc
hai
titer
fig
sc
deliveri
vaccin
construct
fail
elicit
detect
antibodi
respons
second
studi
compar
level
replic
immunogen
protect
efficaci
ndv
vaccin
deliv
combin
init
rout
rout
alon
fig
tabl
previous
shown
ndvbc
express
protein
sarscov
ndvbc
induc
protect
immun
respons
agm
deliv
combin
init
rout
present
studi
immun
agm
ndvbc
empti
vector
init
rout
anim
ndvbc
init
rout
anim
rout
anim
four
addit
anim
immun
init
rout
ndvvf
version
lentogen
la
sota
strain
contain
polybas
f
cleavag
site
ndvbc
engin
express
sarscov
protein
day
first
immun
anim
receiv
second
dose
construct
rout
tl
sampl
obtain
initi
vaccin
dose
assess
vector
shed
fig
shed
ndvbc
reduc
compar
ndvbc
empti
vector
suggest
insert
sarscov
orf
attenu
vivo
replic
fig
also
detect
lower
level
shed
anim
immun
ndvbc
rout
suggest
rout
result
reduc
level
replic
shed
detect
anim
immun
ndvvf
suggest
greater
level
attenu
ndvvf
versu
ndvbcbase
construct
serum
sampl
collect
day
ie
day
first
second
vaccin
dose
analyz
ndvspecif
antibodi
hai
assay
sarscovspecif
igg
elisa
sarscovspecif
neutral
antibodi
previous
describ
fig
panel
ac
addit
mucos
antibodi
respons
analyz
quantit
sarscovspecif
iga
tl
sampl
fig
panel
detect
ndvspecif
serum
antibodi
titer
begin
day
first
dose
gradual
increas
later
time
point
fig
fig
ndvbc
induc
greater
respons
compar
ndvvf
also
observ
increas
sarscov
specif
iga
titer
tl
sampl
anim
receiv
vaccin
either
combin
init
rout
rout
alon
fig
specif
anim
receiv
ndvbc
combin
init
rout
demonstr
increas
tl
iga
titer
day
maintain
increas
day
tl
iga
respons
less
consist
ndvvf
group
anim
demonstr
increas
tl
iga
day
larg
wane
day
despit
rel
meager
humor
respons
anim
receiv
ndvbc
rout
alon
demonstr
increas
sspecif
tl
iga
larg
maintain
day
return
near
background
level
day
unabl
detect
statist
signific
differ
group
due
high
animaltoanim
variabl
evalu
protect
efficaci
init
versu
immun
well
ndvbc
versu
ndvvf
anim
challeng
day
combin
init
rout
tcid
sarscov
per
site
day
postchalleng
nw
tl
sampl
collect
evalu
viral
shed
fig
day
anim
euthan
respiratori
tract
tissu
collect
assess
sarscov
replic
quantit
virolog
fig
ihc
histopatholog
analysi
fig
control
anim
high
moder
titer
sarscov
challeng
viru
detect
nw
tl
sampl
fig
respiratori
tract
tissu
fig
sarscov
antigen
easili
detect
ihc
lung
tissu
fig
top
row
tabl
anim
immun
ndvbc
ndvvf
combin
init
rout
littl
sarscov
detect
three
method
contrast
group
immun
ndvbc
rout
alon
level
sarscov
shed
indistinguish
control
group
titer
sarscov
detect
direct
analysi
lung
tissu
larg
indistinguish
control
group
locat
modest
reduct
seen
section
moreov
level
viral
antigen
evalu
ihc
margin
reduc
compar
control
group
histopatholog
examin
bronchial
tissu
demonstr
pronounc
loss
cilia
increas
cellular
infiltr
necrosi
apoptosi
bronchial
epitheli
cell
follow
challeng
ndvbc
control
well
ndvbc
inimmun
group
littl
pulmonari
patholog
detect
initimmun
group
fig
bottom
row
tabl
ndvvf
shown
sinc
ndv
avian
pathogen
hypothes
viru
may
replic
effici
normal
bodi
temperatur
chicken
bodi
temperatur
human
african
green
monkey
respect
temperatur
mucosa
human
nasal
caviti
therefor
infect
monolay
chicken
embryo
fibroblast
cell
monkey
kidney
cell
serial
dilut
ndvbc
incub
monolay
methylcellulos
variou
temperatur
day
respect
fig
b
follow
incub
plaqu
visual
describ
materi
method
plaqu
size
number
determin
within
rang
temperatur
test
signific
differ
viral
titer
observ
data
shown
howev
dramat
reduct
plaqu
size
associ
reduc
temperatur
observ
chicken
cell
lesser
degre
monkey
cell
fig
b
exampl
comparison
plaqu
size
demonstr
reduct
size
cell
size
reduct
cell
suggest
significantli
reduc
viru
growth
lower
temperatur
similarli
signific
differ
observ
plaqu
form
compar
fig
b
contrast
plaqu
size
human
respiratori
pathogen
equal
fig
next
compar
growth
kinet
ndvbc
ndvbc
cell
infect
moi
pfu
fig
pfu
fig
follow
infect
either
moi
replic
ndvbc
ndvbc
substanti
reduc
compar
contrast
replic
significantli
differ
two
temperatur
time
point
separ
set
experi
compar
ndv
antigen
product
follow
infect
moi
pfu
singlestep
growth
fig
pfu
multistep
growth
ndvbc
fig
ndvbc
fig
moi
hlong
incub
clearli
result
much
lower
level
antigen
express
compar
fig
low
moi
pfu
infect
result
detect
viral
antigen
h
regardless
temperatur
fig
c
howev
h
abund
antigen
cell
incub
detect
express
ndv
cell
incub
moreov
observ
reduc
antigen
accumul
h
cell
incub
taken
togeth
data
indic
reduc
temperatur
upper
respiratori
tract
african
green
monkey
abil
ndv
replic
produc
viral
antigen
greatli
reduc
data
repres
first
direct
comparison
immunogen
protect
efficaci
ndvvector
vaccin
construct
follow
inocul
variou
rout
nonhuman
primat
model
data
suggest
ndvvector
vaccin
requir
deliveri
respiratori
tract
parenter
deliveri
inject
even
two
dose
ineffect
ii
effect
respiratori
tract
immun
deliveri
requir
iii
mesogen
strain
ndv
margin
immunogen
modifi
lentogen
strain
contain
polybas
f
cleavag
site
two
strain
equal
protect
previous
publish
data
mous
model
demonstr
high
immunogen
protect
efficaci
ndvvector
vaccin
administ
iv
ip
rout
although
test
particular
rout
immun
would
appropri
human
use
lack
detect
respons
even
two
dose
deliv
sc
rout
suggest
deliveri
respiratori
tract
requir
immunogen
ndvvector
vaccin
primat
anoth
studi
util
mous
model
demonstr
greater
immunogen
protect
efficaci
immun
compar
iv
ip
administr
howev
oppos
primat
model
inocul
mice
typic
result
deliveri
upper
lower
respiratori
tract
exampl
inocul
balbc
mice
inoculum
result
deliveri
respect
inoculum
lung
therefor
mous
model
allow
distinct
vaccin
deliveri
upper
lower
respiratori
tract
furthermor
alreadi
note
low
phylogenet
anatom
related
mous
human
necessit
use
relev
model
assess
optim
rout
deliveri
ndvvector
vaccin
complet
lack
detect
immun
respons
ndvvector
vaccin
administ
inject
might
explain
tropism
viru
epitheli
tissu
respiratori
tract
henc
restrict
replic
site
howev
lack
signific
immunogen
vaccin
alon
surpris
deliveri
success
use
vaccin
human
nonhuman
primat
human
influenza
virus
respiratori
syncyti
viru
parainfluenza
virus
vaccinia
viru
immun
ndv
result
differ
outcom
note
infect
human
nonhuman
primat
live
attenu
vaccin
human
influenza
viru
respiratori
syncyti
viru
parainfluenza
virus
result
effici
viral
replic
upper
lower
respiratori
tract
contrast
direct
analysi
respiratori
tract
tissu
init
immun
nonhuman
primat
ndv
detect
viru
lung
nasal
turbin
ab
brm
plc
unpublish
data
addit
ndv
replic
ineffici
lower
respiratori
tract
administ
compar
combin
init
rout
fig
thu
appear
contrast
human
virus
avian
ndv
replic
poorli
upper
respiratori
tract
primat
properti
could
account
reduc
immunogen
one
possibl
explan
might
lower
densiti
ndv
receptor
upper
respiratori
tract
primat
compar
lower
respiratori
tract
therefor
lower
level
replic
viru
inocul
exampl
low
transmiss
highli
pathogen
avian
influenza
viru
human
suggest
relat
lack
receptor
sialic
acid
molecul
link
galactos
human
upper
respiratori
tract
sialic
acid
also
serv
receptor
ndv
receptorbind
protein
hn
howev
ndv
appear
less
restrict
influenza
viru
requir
certain
modif
sialic
acid
molecul
receptor
review
therefor
explan
seem
unlik
anoth
possibl
nsv
replic
poorli
upper
respiratori
tract
primat
due
lower
temperatur
site
reflect
adapt
viru
bird
alreadi
note
higher
bodi
temperatur
idea
ndv
restrict
upper
respiratori
tract
due
lower
temperatur
support
signific
reduct
ndvbc
plaqu
size
observ
cell
cultur
incub
perform
lower
temperatur
characterist
upper
respiratori
tract
primat
contrast
reduct
observ
human
respiratori
pathogen
fig
moreov
product
viru
singleand
multicycl
growth
experi
strongli
reduc
ndvbc
ndvbc
fig
associ
reduc
delay
product
intracellular
ndv
antigen
fig
observ
replic
reduc
suggest
reduc
express
replic
ndv
reduc
temperatur
intrins
properti
viru
rather
artifact
due
reduc
cellular
metabol
thu
abil
human
virus
human
influenza
respiratori
syncyti
viru
parainfluenza
virus
effici
replic
upper
respiratori
tract
provid
spread
lower
respiratori
tract
dendrit
cell
antigenpres
cell
abundantli
present
contrast
suggest
ineffici
antigen
express
reduc
viru
product
ndv
upper
respiratori
tract
primat
result
reduc
spread
lower
respiratori
tract
reduc
immun
stimul
two
import
conclus
develop
ndvvector
human
vaccin
made
studi
first
sinc
deliveri
alon
appear
ineffect
primat
model
nebul
deliveri
vaccin
lower
respiratori
tract
may
viabl
option
subsequ
clinic
trial
nebul
deliveri
measl
vaccin
children
found
safe
effect
inexpens
second
sinc
mesogen
modifi
lentogen
strain
ndv
appear
almost
equal
immunogen
equal
protect
choic
strain
develop
human
vaccin
base
factor
immunogen
issu
safeti
human
bird
popul
well
abil
grow
viru
high
titer
substrat
approv
human
vaccin
product
review
critic
consider
move
forward
clinic
trial
vaccin
candid
assist
hai
elisa
assay
project
fund
part
intramur
research
program
niaid
nih
tabl
mean
increas
rel
day
se
fold
group
tl
sampl
collect
concentr
analyz
iga
isotypespecif
elisa
purifi
sarscov
start
dilut
log
valu
anim
record
log
serum
dilut
result
absorb
nm
doubl
background
greater
valu
limit
detect
assign
valu
log
account
variabl
sampl
collect
concentr
titer
normal
total
iga
mass
sampl
determin
quantit
total
iga
elisa
day
mean
normal
log
background
titer
group
follow
fig
anim
challeng
sarscov
day
euthan
day
postchalleng
tissu
sampl
taken
indic
region
duplic
tissu
sampl
anim
homogen
viral
titer
determin
mean
log
titer
se
group
shown
limit
detect
log
indic
dot
line
titer
limit
assign
valu
log
tcid
g
mean
se
valu
shown
p
valu
calcul
compar
mean
titer
experiment
group
control
group
use
repeat
measur
twoway
anova
bonferroni
posthoc
analysi
p
p
p
immunohistochem
histopatholog
character
lung
tissu
sampl
african
green
monkey
immun
ndv
vector
vaccin
challeng
sarscov
